Idorsia IDIA

SWX: IDIA | ISIN: CH0363463438   1/07/2025
2,180 CHF (+1,40%)
(+1,40%)   1/07/2025

30 juni 2025 · A factory in a lab: Idorsia's breakthrough synthetic glycan vaccine platform validated for the first time in humans · Persbericht

25 juni 2025 · Bondholders approve amended terms of the 2025 and 2028 convertible bonds · Persbericht

25 juni 2025 · Idorsia launches repurchase offer for its 2025 and 2028 convertible bonds · Persbericht

23 juni 2025 · Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement · Persbericht

10 juni 2025 · Idorsia announces the appointment of Srishti Gupta, MD as CEO to ensure the long-term success of Idorsia · Persbericht

6 juni 2025 · Idorsia publishes invitations to bondholder meetings · Persbericht

28 mei 2025 · Shareholders vote in favor of all proposals by the Board at Idorsia’s Annual General Meeting 2025 · Persbericht

21 mei 2025 · New funds secured – allowing the commercial ramp-up of QUVIVIQ to accelerate Idorsia’s path to profitability · Persbericht

2 mei 2025 · Idorsia issues invitation to the 2025 Annual General Meeting of Shareholders · Persbericht

30 april 2025 · Idorsia announces financial results for the first quarter 2025 – QUVIVIQ taking off in Europe and TRYVIO REMS removal increases the value of this outstanding asset · Persbericht

29 april 2025 · New data with daridorexant assessing the transition from night to day in insomnia disorder published in Sleep Medicine · Persbericht

16 april 2025 · Higher cantonal composition authority approved the amendments to the terms of the 2025 convertible bond · Persbericht

9 april 2025 · The effect of aprocitentan for reducing blood pressure and proteinuria in Black patients with resistant hypertension published in Hypertension · Persbericht

9 april 2025 · US FDA approves an updated label for TRYVIO (aprocitentan) removing the REMS requirement · Persbericht

27 maart 2025 · Idorsia publishes its Annual Report 2024 · Persbericht

17 maart 2025 · US FDA removes REMS requirement for TRYVIO (aprocitentan) – minimizing the burden on the healthcare delivery systems and patients · Persbericht

14 maart 2025 · Idorsia announces the publication of positive data with daridorexant in patients with chronic insomnia and nocturia · Persbericht

4 maart 2025 · Idorsia announces financial results for 2024 · Persbericht

27 februari 2025 · Invitation to Idorsia's Full Year 2024 Financial Reporting webcast and conference call · Persbericht

26 februari 2025 · Idorsia reaches an agreement with significant bondholders to restructure its convertible bond debt and to secure funding for future operations · Persbericht

Mijn selecties